CLINICAL TRIAL OF DESIPRAMINE IN THE TREATMENT OF DEPRESSION
Abstract
Thirty severely depressed patients received daily oral doses of 75 or 100 mg. desipramine, a metabolite of imipramine. Duration of therapy averaged 3 to 4 months and dosage was decreased gradually according to individual progress. Tranquilizers were used as required to control anxiety, insomnia or agitation, and psychotherapy was given at the level indicated.
Most patients had a history of several depressive episodes, hospitalizations, ECT, or poor response to numerous other drugs.
In 24 patients (80%) desipramine produced a satisfactory clinical response. The new drug exerted a faster onset of action (usually 2 to 7 days) and fewer, milder side effects compared to previous use of imipramine.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).